Becton, Dickinson and Company (U.S.) and Pfizer Inc.(U.S.) are Leading Players in the Injectable Drug Delivery Market
The Injectable drug delivery market is projected to reach USD 1139.4 billion by 2029 from USD 754.5 billion in 2024, at a CAGR of 8.6% from 2024 to 2029. The market is growing significantly due to the prevalence of Infectious diseases, advancements in the field of biotechnology and nanotechnology, increasing geriatric populations, and funding from government agencies for research and drug developments.
The Injectable drug delivery market is highly consolidated and is dominated by key players. The major players operating in this market are Becton, Dickinson and Company (U.S.), Pfizer Inc.(U.S.), Johnson & Johnson (U.S), Teva Pharmaceuticals Industries Ltd.( Israel), Eli Lilly and Company (U.S), Baxter International, Inc.( U.S), Schott AG (Germany), Gerresheimer (Germany), B.Braun Melsungen (Germany).
To know about the assumptions considered for the study download the pdf brochure
BECTON, DICKINSON AND COMPANY ( U.S)
BD's headquarters are in Franklin Lakes, New Jersey, and the company is well-known both in the US and Canada. Operating throughout North America are production plants, R&D centers, distribution centers, and sales offices of the corporation.
BD (Becton, Dickinson, and Company is a global medical technology leader that creates, manufactures and sells a diverse variety of medical devices, instrument systems, and reagents. With a focus on enhancing healthcare delivery and patient outcomes, BD's innovative products and solutions play an important role in injectable drug administration.
BD's contributions to injectable drug delivery can be appreciated through its varied array of devices and technologies that enable the safe, accurate, and efficient administration of injectable pharmaceuticals.BD is well-known for its safety-engineered syringes and needles, which reduce needlestick injuries and improve healthcare worker safety during injection procedures.
In order to reduce the risk of needlestick injuries and improve worker safety in the healthcare industry, BD produces a large selection of syringes and needles with safety features. Among these products are:
Insulin syringe with built-in needle shielding device, BD SafetyGlideNeedles.
BD Eclipse Needle: a safety needle that comes pre-attached and has a shielding mechanism.
A syringe having a retractable needle mechanism for safe disposal is the BD Safety-LokSyringe.
The BD UltraSafe Plus Passive Needle Guard is a syringe designed to be activated with one hand only.
PFIZER,INC.( U.S)
Pfizer is one of the world's major pharmaceutical firms, with a diverse portfolio of prescription medications, vaccines, and consumer healthcare goods. The organization operates in over 125 countries, meeting healthcare requirements across a wide range of therapeutic disciplines. Pfizer provides an extensive portfolio of injectable drugs in a variety of therapeutic areas, including oncology, inflammation, infectious illnesses, cardiovascular diseases, and vaccinations. These injectable medicines are essential for treating acute and chronic illnesses and are administered via intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. Pfizer has a major presence in biologics and biosimilars, which include injectable biologic medicines as well as biosimilar versions of existing biologic pharmaceuticals. These medications address major medical needs such as cancer, autoimmune disorders, and chronic diseases, and they frequently require injectable delivery for maximum performance.
ELI LILLY AND COMPANY (U.S)
Eli Lilly is a global pharmaceutical leader with operations in more than 120 countries. The company develops medicines for a variety of medical disorders, including diabetes, oncology, neurology, immunology, and cardiovascular illnesses.Lilly has a substantial position in the diabetes care industry, offering a variety of injectable drugs to treat diabetes mellitus. These include insulin products like Humalog (insulin lispro) and Basaglar (insulin glargine), as well as GLP-1 receptor agonists like Trulicity (dulaglutide) and tirzepatide, which are given by injection. Lilly is a pioneer in the creation of biologic treatments and monoclonal antibodies to treat autoimmune illnesses, cancer, and other medical ailments. Many of these biologic medications are administered via injection and necessitate sophisticated drug delivery systems to ensure proper dose and efficacy. Lilly's oncology portfolio comprises injectable drugs used to treat a variety of diseases, including breast cancer, lung cancer, and leukaemia. Chemotherapy drugs, targeted therapies, and immunotherapies are examples of intravenous or subcutaneously delivered treatments.
Related Reports:
Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious diseases,Cancer), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), Distribution Channel ,Patient Care Setting, & Region - Global Forecast to 2029
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
